|  |
| --- |
| Table S1. Clinicopathological features of 11 AITL cases at initial diagnosis or relapse |
| Case | B symptom | Associated | WBC  | Lymphocyte | IgG  | IgM | IgA  | LDH | HTLV | PD1 | ICOS | BCL6 | CD10 | T-cell | B-cell |
|  |  | condition |  (/μL ) | (%) | (mg/dL) | (mg/dL) | (mg/dL) | (U/L) | (serum) |  |  |  |  | clonality | clonality |
| 1 | Yes | BM involvement | 84400 | 22.2 | 795 | 140 | 64 | 1220 | - | 1+ | 1+ | 1+ | - | NT | Yes |
| 2-1 | Yes | CAD; BM involvement | 3800 | 9.0  | 4210 | 66 | 394 | 343 | - | 1+ | 1+ | 1+ | 1+ | M | No |
| 2/2 | Yes | CAD; BM involvement | 5020 | 25.1 | 2660 | 153 | 1520 | 382 | - | 1+ | 1+ | 1+ | 1+ | NT | \*Yes |
| 3 | Yes | IgG4+ CD; BM, chest wall and pleural involvement | 21190 | 56.5 | 5960 | 1000 | 248 | 469 | - | 1+ | 1+ | 1+ | *
 | NT | No |
| 4 | Yes | No | 3360 | 6.3 | 1070 | 334 | 327 | 290 | - | 2+ | 2+ | NA | NA | NT | No |
| 5 | No | No | 6060 | 24.8 | 1880 | 485 | 65 | N/A | - | 1+ | 1 | 1+ | - | NT | No |
| 6 | Yes | No | 10440 | 39.0 | 852 | 90 | 360 | 235 | - | 2+ | 2+ | 2+ | - | NT | Yes |
| 7 | Yes | skin lesions | 3400 | 21.2 | 1600 | 341 | 817 | 372 | - | 2+ | 2+ | 2+ | - | NT | No |
| 8 | No | skin lesions | 4890 | 25.2 | NT | NT | NT | 228 | - | 2+ | 2+ | NA | NA | NT | N/A |
| 9 | Yes | skin lesions | 7720 | 7.1 | 1270 | 290 | 431 | 285 | - | 2+ | - | 1+ | 1+ | NT | No |
| 10 | No | No | 4900 | 24.0 | 845 | 285 | 109 | 202 | - | 1+ | 1+ | 1+ | - | M | No |
| 11 | Yes | skin lesions | 12350 | 60.8 | NT | NT | NT | 345 | - | 1+ | 1+ | 1+ | - | M | No |
| \* Monoclonal in a polyclonal backgroundAITL, angioimmunoblastic T-cell lymphoma; BM: bone marrow; CAD, cold agglutinin disease; CD, Castleman disease; HTLV, human T-lymphotropic virus; NT, not testedReference range, WBC: 3500-11000/μL; Lymphocyte; 20-56%; IgG: 700-1600 mg/dL; IgA: 70-400 mg/dL; IgM: 40-230 mg/dL; LDH:135-225 U/L |